CA3022528A1 - Automated and manual methods for isolation of extracellular vesicles and co-isolation of cell-free dna from biofluids - Google Patents
Automated and manual methods for isolation of extracellular vesicles and co-isolation of cell-free dna from biofluids Download PDFInfo
- Publication number
- CA3022528A1 CA3022528A1 CA3022528A CA3022528A CA3022528A1 CA 3022528 A1 CA3022528 A1 CA 3022528A1 CA 3022528 A CA3022528 A CA 3022528A CA 3022528 A CA3022528 A CA 3022528A CA 3022528 A1 CA3022528 A1 CA 3022528A1
- Authority
- CA
- Canada
- Prior art keywords
- bead
- dna
- rna
- biological sample
- capture surface
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 285
- 238000002955 isolation Methods 0.000 title claims abstract description 66
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 199
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 199
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 199
- 239000012472 biological sample Substances 0.000 claims abstract description 114
- 239000011324 bead Substances 0.000 claims description 108
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 106
- 239000012528 membrane Substances 0.000 claims description 98
- 239000000523 sample Substances 0.000 claims description 86
- 238000000605 extraction Methods 0.000 claims description 66
- 108090000623 proteins and genes Proteins 0.000 claims description 57
- 238000005342 ion exchange Methods 0.000 claims description 55
- 239000007787 solid Substances 0.000 claims description 53
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 40
- 210000002700 urine Anatomy 0.000 claims description 37
- 239000000872 buffer Substances 0.000 claims description 30
- 239000003795 chemical substances by application Substances 0.000 claims description 30
- 230000005291 magnetic effect Effects 0.000 claims description 30
- 239000012149 elution buffer Substances 0.000 claims description 29
- 102000004169 proteins and genes Human genes 0.000 claims description 27
- 235000018102 proteins Nutrition 0.000 claims description 26
- 238000003556 assay Methods 0.000 claims description 25
- 230000006920 protein precipitation Effects 0.000 claims description 24
- 210000002381 plasma Anatomy 0.000 claims description 23
- 239000000126 substance Substances 0.000 claims description 23
- 238000001914 filtration Methods 0.000 claims description 20
- 239000000377 silicon dioxide Substances 0.000 claims description 20
- 230000027455 binding Effects 0.000 claims description 18
- 238000005119 centrifugation Methods 0.000 claims description 18
- 238000000746 purification Methods 0.000 claims description 17
- -1 DNAse Proteins 0.000 claims description 16
- 239000003599 detergent Substances 0.000 claims description 15
- 239000006172 buffering agent Substances 0.000 claims description 14
- 108091005804 Peptidases Proteins 0.000 claims description 13
- 239000003638 chemical reducing agent Substances 0.000 claims description 13
- 210000002966 serum Anatomy 0.000 claims description 13
- 238000010828 elution Methods 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 11
- 108091070501 miRNA Proteins 0.000 claims description 11
- 238000003753 real-time PCR Methods 0.000 claims description 10
- 239000002202 Polyethylene glycol Substances 0.000 claims description 9
- 229920001223 polyethylene glycol Polymers 0.000 claims description 9
- 238000010839 reverse transcription Methods 0.000 claims description 9
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 8
- 102000035195 Peptidases Human genes 0.000 claims description 8
- 150000001450 anions Chemical class 0.000 claims description 8
- 210000001808 exosome Anatomy 0.000 claims description 8
- 230000005294 ferromagnetic effect Effects 0.000 claims description 8
- 229910001428 transition metal ion Inorganic materials 0.000 claims description 8
- 108091032955 Bacterial small RNA Proteins 0.000 claims description 7
- 150000001412 amines Chemical group 0.000 claims description 7
- 230000029087 digestion Effects 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 235000019833 protease Nutrition 0.000 claims description 7
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical group [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 6
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 6
- 150000001768 cations Chemical class 0.000 claims description 6
- 239000002679 microRNA Substances 0.000 claims description 6
- 239000001632 sodium acetate Substances 0.000 claims description 6
- 235000017281 sodium acetate Nutrition 0.000 claims description 6
- 229910052725 zinc Inorganic materials 0.000 claims description 6
- 239000011701 zinc Substances 0.000 claims description 6
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 5
- 229920000642 polymer Polymers 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 4
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical group OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 claims description 4
- 239000012928 buffer substance Substances 0.000 claims description 4
- 230000008859 change Effects 0.000 claims description 4
- 239000002738 chelating agent Substances 0.000 claims description 4
- 238000007254 oxidation reaction Methods 0.000 claims description 4
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 4
- 150000003512 tertiary amines Chemical class 0.000 claims description 4
- 102000006382 Ribonucleases Human genes 0.000 claims description 3
- 108010083644 Ribonucleases Proteins 0.000 claims description 3
- 238000012545 processing Methods 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 229920002527 Glycogen Polymers 0.000 claims description 2
- 101150084233 ago2 gene Proteins 0.000 claims description 2
- 230000006862 enzymatic digestion Effects 0.000 claims description 2
- 229940096919 glycogen Drugs 0.000 claims description 2
- 150000002500 ions Chemical class 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 235000004252 protein component Nutrition 0.000 claims description 2
- 230000007704 transition Effects 0.000 claims description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical group SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 claims 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 abstract description 8
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 abstract description 5
- 108020004414 DNA Proteins 0.000 description 127
- 239000002245 particle Substances 0.000 description 55
- 239000000090 biomarker Substances 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 25
- 201000010099 disease Diseases 0.000 description 24
- 239000012530 fluid Substances 0.000 description 20
- 238000004458 analytical method Methods 0.000 description 19
- 230000009089 cytolysis Effects 0.000 description 19
- 238000001514 detection method Methods 0.000 description 19
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 19
- 210000001124 body fluid Anatomy 0.000 description 15
- 206010028980 Neoplasm Diseases 0.000 description 14
- 239000003153 chemical reaction reagent Substances 0.000 description 13
- 230000035772 mutation Effects 0.000 description 12
- 238000003199 nucleic acid amplification method Methods 0.000 description 12
- 239000003161 ribonuclease inhibitor Substances 0.000 description 11
- 230000003321 amplification Effects 0.000 description 10
- 239000011159 matrix material Substances 0.000 description 10
- 108020004999 messenger RNA Proteins 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 238000000108 ultra-filtration Methods 0.000 description 10
- 238000003745 diagnosis Methods 0.000 description 9
- 238000012544 monitoring process Methods 0.000 description 8
- 238000003752 polymerase chain reaction Methods 0.000 description 8
- 239000011148 porous material Substances 0.000 description 8
- 239000011534 wash buffer Substances 0.000 description 8
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 8
- 241000700605 Viruses Species 0.000 description 7
- 230000002411 adverse Effects 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 239000012160 loading buffer Substances 0.000 description 7
- 241001534160 Escherichia virus Qbeta Species 0.000 description 6
- 238000012369 In process control Methods 0.000 description 6
- 108700011259 MicroRNAs Proteins 0.000 description 6
- 239000004365 Protease Substances 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000002255 enzymatic effect Effects 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 238000010965 in-process control Methods 0.000 description 6
- 239000013017 sartobind Substances 0.000 description 6
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 5
- 101710132601 Capsid protein Proteins 0.000 description 5
- 101710094648 Coat protein Proteins 0.000 description 5
- 101710125418 Major capsid protein Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 101710141454 Nucleoprotein Proteins 0.000 description 5
- 239000004695 Polyether sulfone Substances 0.000 description 5
- 101710083689 Probable capsid protein Proteins 0.000 description 5
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 5
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000011068 loading method Methods 0.000 description 5
- 230000002934 lysing effect Effects 0.000 description 5
- 239000012139 lysis buffer Substances 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 229920006393 polyether sulfone Polymers 0.000 description 5
- 238000007781 pre-processing Methods 0.000 description 5
- 238000004393 prognosis Methods 0.000 description 5
- 235000019419 proteases Nutrition 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 238000003757 reverse transcription PCR Methods 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 108020004635 Complementary DNA Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 108020004566 Transfer RNA Proteins 0.000 description 4
- 239000012148 binding buffer Substances 0.000 description 4
- 238000010804 cDNA synthesis Methods 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 230000004077 genetic alteration Effects 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000001338 necrotic effect Effects 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 239000004627 regenerated cellulose Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 239000011592 zinc chloride Substances 0.000 description 4
- 235000005074 zinc chloride Nutrition 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 241000713887 Human endogenous retrovirus Species 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- 238000002123 RNA extraction Methods 0.000 description 3
- 238000010240 RT-PCR analysis Methods 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 239000013504 Triton X-100 Substances 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000000658 coextraction Methods 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 239000000356 contaminant Substances 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 238000001085 differential centrifugation Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000005227 gel permeation chromatography Methods 0.000 description 3
- 239000000383 hazardous chemical Substances 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000007481 next generation sequencing Methods 0.000 description 3
- 125000001453 quaternary ammonium group Chemical group 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 108020004418 ribosomal RNA Proteins 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- RSGFPIWWSCWCFJ-VAXZQHAWSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O RSGFPIWWSCWCFJ-VAXZQHAWSA-N 0.000 description 2
- 108091023037 Aptamer Proteins 0.000 description 2
- 239000007989 BIS-Tris Propane buffer Substances 0.000 description 2
- OABOXRPGTFRBFZ-IMJSIDKUSA-N Cys-Cys Chemical compound SC[C@H](N)C(=O)N[C@@H](CS)C(O)=O OABOXRPGTFRBFZ-IMJSIDKUSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 2
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 108091027305 Heteroduplex Proteins 0.000 description 2
- 241000714210 Leviviridae Species 0.000 description 2
- 108060004795 Methyltransferase Proteins 0.000 description 2
- 108010006519 Molecular Chaperones Proteins 0.000 description 2
- 102000005431 Molecular Chaperones Human genes 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 229920012266 Poly(ether sulfone) PES Polymers 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000007844 allele-specific PCR Methods 0.000 description 2
- 210000004381 amniotic fluid Anatomy 0.000 description 2
- 210000003567 ascitic fluid Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- HHKZCCWKTZRCCL-UHFFFAOYSA-N bis-tris propane Chemical compound OCC(CO)(CO)NCCCNC(CO)(CO)CO HHKZCCWKTZRCCL-UHFFFAOYSA-N 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 210000002726 cyst fluid Anatomy 0.000 description 2
- 108010004073 cysteinylcysteine Proteins 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000011143 downstream manufacturing Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002270 exclusion chromatography Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000020256 human milk Nutrition 0.000 description 2
- 210000004251 human milk Anatomy 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000004880 lymph fluid Anatomy 0.000 description 2
- 210000004324 lymphatic system Anatomy 0.000 description 2
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 210000002445 nipple Anatomy 0.000 description 2
- 108091027963 non-coding RNA Proteins 0.000 description 2
- 102000042567 non-coding RNA Human genes 0.000 description 2
- 238000007826 nucleic acid assay Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 238000002205 phenol-chloroform extraction Methods 0.000 description 2
- 210000004910 pleural fluid Anatomy 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 2
- 239000012465 retentate Substances 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000003196 serial analysis of gene expression Methods 0.000 description 2
- 239000004055 small Interfering RNA Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000000123 temperature gradient gel electrophoresis Methods 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 229910052723 transition metal Inorganic materials 0.000 description 2
- 150000003624 transition metals Chemical class 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- NLMKTBGFQGKQEV-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hexadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO NLMKTBGFQGKQEV-UHFFFAOYSA-N 0.000 description 1
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- GUQQBLRVXOUDTN-XOHPMCGNSA-N 3-[dimethyl-[3-[[(4r)-4-[(3r,5s,7r,8r,9s,10s,12s,13r,14s,17r)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]propyl]azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CC(O)CS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 GUQQBLRVXOUDTN-XOHPMCGNSA-N 0.000 description 1
- 101710159080 Aconitate hydratase A Proteins 0.000 description 1
- 101710159078 Aconitate hydratase B Proteins 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 230000007067 DNA methylation Effects 0.000 description 1
- 108091007413 Extracellular RNA Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 108010047956 Nucleosomes Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 108091007412 Piwi-interacting RNA Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 101710105008 RNA-binding protein Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004688 Small Nuclear RNA Proteins 0.000 description 1
- 102000039471 Small Nuclear RNA Human genes 0.000 description 1
- 108020003224 Small Nucleolar RNA Proteins 0.000 description 1
- 102000042773 Small Nucleolar RNA Human genes 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 210000002583 cell-derived microparticle Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000008711 chromosomal rearrangement Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000007418 data mining Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000003935 denaturing gradient gel electrophoresis Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 239000003302 ferromagnetic material Substances 0.000 description 1
- 239000010200 folin Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000003014 ion exchange membrane Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000011528 liquid biopsy Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 238000010801 machine learning Methods 0.000 description 1
- 230000005389 magnetism Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- ZIYVHBGGAOATLY-UHFFFAOYSA-N methylmalonic acid Chemical compound OC(=O)C(C)C(O)=O ZIYVHBGGAOATLY-UHFFFAOYSA-N 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 229920000344 molecularly imprinted polymer Polymers 0.000 description 1
- 210000002487 multivesicular body Anatomy 0.000 description 1
- CGVLVOOFCGWBCS-RGDJUOJXSA-N n-octyl β-d-thioglucopyranoside Chemical compound CCCCCCCCS[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CGVLVOOFCGWBCS-RGDJUOJXSA-N 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 210000001623 nucleosome Anatomy 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 238000000710 polymer precipitation Methods 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000011045 prefiltration Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000012799 strong cation exchange Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000009452 underexpressoin Effects 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
- C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Analytical Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662336203P | 2016-05-13 | 2016-05-13 | |
| US62/336,203 | 2016-05-13 | ||
| PCT/US2017/032719 WO2017197399A1 (en) | 2016-05-13 | 2017-05-15 | Automated and manual methods for isolation of extracellular vesicles and co-isolation of cell-free dna from biofluids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3022528A1 true CA3022528A1 (en) | 2017-11-16 |
Family
ID=59014730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3022528A Pending CA3022528A1 (en) | 2016-05-13 | 2017-05-15 | Automated and manual methods for isolation of extracellular vesicles and co-isolation of cell-free dna from biofluids |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US10808240B2 (enExample) |
| EP (2) | EP4079853A1 (enExample) |
| JP (2) | JP7037504B2 (enExample) |
| CN (1) | CN109642229A (enExample) |
| AU (1) | AU2017263886B2 (enExample) |
| CA (1) | CA3022528A1 (enExample) |
| WO (1) | WO2017197399A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110106169A (zh) * | 2019-05-28 | 2019-08-09 | 浙江大学 | 一种提高无细胞体液中微量核酸捕获率的方法 |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11268085B2 (en) * | 2014-05-27 | 2022-03-08 | Exosome Diagnostics, Inc. | Methods for isolating microvesicles and extracting nucleic acids from biological samples |
| US10808240B2 (en) | 2016-05-13 | 2020-10-20 | Exosome Diagnostics, Inc. | Automated and manual methods for isolation of extracellular vesicles and co-isolation of cell-free DNA from biofluids |
| KR20190100174A (ko) | 2016-12-23 | 2019-08-28 | 엑소팜 리미티드 | 미세소포 및 엑소좀의 정제 또는 단리를 위한 방법 및 조성물 |
| KR101875594B1 (ko) * | 2017-01-13 | 2018-07-06 | ㈜로제타엑소좀 | 금속을 이용한 세포밖 소포체의 분리 방법 |
| EP3635139A1 (en) | 2017-05-17 | 2020-04-15 | Exosome Diagnostics, Inc. | Microvesicle nucleic acids and/or proteins and uses thereof as markers of renal transplant rejection |
| CN111148828A (zh) * | 2017-07-26 | 2020-05-12 | 罗塞塔外排体株式会社 | 利用阳离子分离细胞外囊泡的方法 |
| EP3807616A4 (en) * | 2018-06-18 | 2022-03-23 | Exopharm Limited | METHODS AND COMPOSITIONS FOR PURIFICATION OR ISOLATION OF MICROVESICLES AND EXOSOMES |
| WO2020077294A1 (en) * | 2018-10-12 | 2020-04-16 | Simpore, Inc. | Extracellular vesicle isolation by nanomembranes |
| WO2020106853A1 (en) | 2018-11-20 | 2020-05-28 | Exosome Diagnostics, Inc. | Compositions and methods for internal controls of microvesicle isolations |
| CN111254138A (zh) * | 2018-12-03 | 2020-06-09 | 北京银丰鼎诚生物工程技术有限公司 | 一种分子克隆中提高酶切产物浓缩效率的方法 |
| EP3941607A1 (en) | 2019-03-21 | 2022-01-26 | Codiak BioSciences, Inc. | Process for preparing extracellular vesicles |
| GB201906722D0 (en) * | 2019-05-13 | 2019-06-26 | Ttp Plc | A method of preparing a sample for a diagnostic assay |
| EP4031865A2 (en) | 2019-09-18 | 2022-07-27 | Exosome Diagnostics, Inc. | Compositions, methods, and kits for the isolation of extracellular vesicles |
| EP4077659A1 (en) | 2019-12-16 | 2022-10-26 | QIAGEN GmbH | Enrichment method |
| EP4077660A1 (en) | 2019-12-16 | 2022-10-26 | QIAGEN GmbH | Method for enriching vesicular rna |
| JP2023508411A (ja) * | 2019-12-23 | 2023-03-02 | バイオプセンス オサケユキチュア | 血液試料からセルフリー核酸を抽出するための方法、自動化システムおよびカートリッジ |
| CN115461445A (zh) * | 2020-04-15 | 2022-12-09 | 合同会社予幸集团中央研究所 | 细胞外囊泡的回收方法 |
| WO2021217173A1 (en) * | 2020-04-21 | 2021-10-28 | Siemens Healthcare Diagnostics Inc. | Clinical specimen collection swabs for molecular diagnostic applications and methods of production and use thereof |
| US20230203587A1 (en) | 2020-05-29 | 2023-06-29 | Exosome Diagnostics, Inc. | Use of microvesicle signature for the diagnosis and treatment of kidney transplant rejection |
| WO2022066934A2 (en) * | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Process for preparing extracellular vesicles |
| CZ35067U1 (cs) * | 2020-12-15 | 2021-05-18 | Univerzita Palackého v Olomouci | Sada pro izolaci RNA |
| JP7773765B2 (ja) * | 2020-12-18 | 2025-11-20 | 国立研究開発法人産業技術総合研究所 | 回収用キットおよび核酸含有溶液の調製方法 |
| US20220315992A1 (en) * | 2021-04-06 | 2022-10-06 | ID Match, LLC | Method for identification of urine drug testing sample |
| WO2022263500A1 (en) * | 2021-06-17 | 2022-12-22 | Qiagen Gmbh | Method for isolating non-vesicular mirna |
| US20250075258A1 (en) | 2021-07-16 | 2025-03-06 | Exosome Diagnostics, Inc. | Methods of detecting sjogren's syndrome using salivary exosomes |
| DE102021208893B3 (de) | 2021-08-13 | 2022-11-17 | Hahn-Schickard-Gesellschaft für angewandte Forschung e.V. | Isolieren von Analyten unterschiedlicher Analyt-Klassen |
| SE2100130A1 (en) * | 2021-09-01 | 2023-03-02 | Frontline Diagnostics AB | System for integrated automated isolation and analysis of biological vesicles and associated molecules |
| US20250009797A1 (en) * | 2021-11-04 | 2025-01-09 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| AU2023221644A1 (en) | 2022-02-18 | 2024-09-12 | Bio-Techne Corporation | Use of microvesicle signatures in the identification and treatment of renal disorders |
| WO2024054572A1 (en) | 2022-09-07 | 2024-03-14 | Exosome Diagnostics, Inc. | Methods of detecting sjögren's syndrome using salivary exosomes |
| WO2024185655A1 (ja) * | 2023-03-06 | 2024-09-12 | 東ソー株式会社 | 細胞外小胞精製用磁性粒子およびその製造方法、ならびに、細胞外小胞の精製方法 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5639611A (en) | 1988-12-12 | 1997-06-17 | City Of Hope | Allele specific polymerase chain reaction |
| US5219727A (en) | 1989-08-21 | 1993-06-15 | Hoffmann-Laroche Inc. | Quantitation of nucleic acids using the polymerase chain reaction |
| AU645915B2 (en) | 1991-07-23 | 1994-01-27 | F. Hoffmann-La Roche Ag | Improvements in the in situ PCR |
| US5605798A (en) | 1993-01-07 | 1997-02-25 | Sequenom, Inc. | DNA diagnostic based on mass spectrometry |
| US5639606A (en) | 1993-04-06 | 1997-06-17 | The University Of Rochester | Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction |
| US5556773A (en) | 1993-08-06 | 1996-09-17 | Yourno; Joseph | Method and apparatus for nested polymerase chain reaction (PCR) with single closed reaction tubes |
| CA2270132A1 (en) | 1996-11-06 | 1998-05-14 | Sequenom, Inc. | Dna diagnostics based on mass spectrometry |
| EP0985148A4 (en) | 1997-05-28 | 2004-03-10 | Inst Medical W & E Hall | DIAGNOSIS OF NUCLEIC ACIDS BY MASS SPECTROMETRY, MASS SEPARATION AND BASE-SPECIFIC CLEAVING |
| US6004755A (en) | 1998-04-07 | 1999-12-21 | Incyte Pharmaceuticals, Inc. | Quantitative microarray hybridizaton assays |
| FR2788780B1 (fr) | 1999-01-27 | 2001-03-30 | Ap Cells Inc | Procede de preparation de vesicules membranaires |
| GB9927320D0 (en) | 1999-11-18 | 2000-01-12 | Chiron Spa | Exosome separation |
| US6812023B1 (en) | 2000-04-27 | 2004-11-02 | Anosys, Inc. | Methods of producing membrane vesicles |
| US6913879B1 (en) | 2000-07-10 | 2005-07-05 | Telechem International Inc. | Microarray method of genotyping multiple samples at multiple LOCI |
| US6696271B2 (en) | 2001-08-23 | 2004-02-24 | The Regents Of The University Of California | Frozen tissue microarray technology for analysis of RNA, DNA, and proteins |
| WO2003023065A1 (en) | 2001-09-06 | 2003-03-20 | Syngenta Participations Ag | Dna methylation patterns |
| ES2431944T3 (es) | 2002-06-26 | 2013-11-28 | Cold Spring Harbor Laboratory | Métodos para determinar los perfiles de metilación |
| AU2003267065A1 (en) | 2002-09-02 | 2004-03-19 | Pamgene B.V. | Novel integrated microarray analysis |
| US7141371B2 (en) | 2002-09-06 | 2006-11-28 | State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon | Methods for detecting and localizing DNA mutations by microarray |
| US7527929B2 (en) | 2004-07-30 | 2009-05-05 | Agencourt Bioscience Corporation | Methods of isolating nucleic acids using multifunctional group-coated solid phase carriers |
| EP1869221A2 (en) | 2005-04-15 | 2007-12-26 | Cedars-Sinai Medical Center | Flow-cytometric heteroduplex analysis for detection of genetic alterations |
| US20060286557A1 (en) * | 2005-06-15 | 2006-12-21 | Basehore Lee S | Combined lysis and PCR buffer |
| US9428746B2 (en) * | 2007-10-31 | 2016-08-30 | Akonni Biosystems, Inc. | Method and kit for purifying nucleic acids |
| WO2011009104A1 (en) * | 2009-07-16 | 2011-01-20 | The General Hospital Corporation | Nucleic acid analysis |
| EP2245199B1 (en) | 2008-02-01 | 2013-11-13 | The General Hospital Corporation | Use of microvesicles in diagnosis, prognosis and treatment of medical diseases and conditions |
| US10767214B2 (en) | 2010-10-28 | 2020-09-08 | Clinical Genomics Pty Ltd | Method of microvesicle enrichment |
| SG190450A1 (en) * | 2010-12-20 | 2013-06-28 | Agency Science Tech & Res | Method of purifying exosomes |
| MX392552B (es) * | 2013-01-03 | 2025-03-11 | Exosome Diagnostics Inc | Métodos para aislar microvesículas. |
| US10619152B2 (en) * | 2014-02-10 | 2020-04-14 | Nancy Quan | Isolation of cell-free nucleic acids from bodily fluid samples using solid chaotropic agents |
| US11268085B2 (en) * | 2014-05-27 | 2022-03-08 | Exosome Diagnostics, Inc. | Methods for isolating microvesicles and extracting nucleic acids from biological samples |
| AU2015287763B2 (en) | 2014-07-09 | 2019-08-08 | Exosome Diagnostics, Inc. | Methods for isolating microvesicles and extracting nucleic acids from biological samples |
| CN104152436B (zh) * | 2014-08-01 | 2017-12-15 | 杭州新景生物试剂开发有限公司 | Dna分离纯化方法及其试剂盒 |
| CA2965500A1 (en) * | 2014-10-24 | 2016-04-28 | Abbott Molecular Inc. | Enrichment of small nucleic acids |
| CN105112400A (zh) * | 2015-08-31 | 2015-12-02 | 臻和（北京）科技有限公司 | 一种提取游离dna的试剂盒 |
| US10808240B2 (en) * | 2016-05-13 | 2020-10-20 | Exosome Diagnostics, Inc. | Automated and manual methods for isolation of extracellular vesicles and co-isolation of cell-free DNA from biofluids |
-
2017
- 2017-05-15 US US16/301,176 patent/US10808240B2/en active Active
- 2017-05-15 EP EP22167997.0A patent/EP4079853A1/en active Pending
- 2017-05-15 WO PCT/US2017/032719 patent/WO2017197399A1/en not_active Ceased
- 2017-05-15 EP EP17728304.1A patent/EP3455355B1/en active Active
- 2017-05-15 CN CN201780043334.9A patent/CN109642229A/zh active Pending
- 2017-05-15 AU AU2017263886A patent/AU2017263886B2/en active Active
- 2017-05-15 JP JP2018559313A patent/JP7037504B2/ja active Active
- 2017-05-15 CA CA3022528A patent/CA3022528A1/en active Pending
-
2020
- 2020-10-19 US US17/074,040 patent/US20210238582A1/en active Pending
-
2022
- 2022-03-04 JP JP2022033452A patent/JP7354327B2/ja active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110106169A (zh) * | 2019-05-28 | 2019-08-09 | 浙江大学 | 一种提高无细胞体液中微量核酸捕获率的方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20210238582A1 (en) | 2021-08-05 |
| JP2022084700A (ja) | 2022-06-07 |
| EP4079853A1 (en) | 2022-10-26 |
| EP3455355A1 (en) | 2019-03-20 |
| US20190284548A1 (en) | 2019-09-19 |
| US10808240B2 (en) | 2020-10-20 |
| AU2017263886A1 (en) | 2018-11-22 |
| JP2019521322A (ja) | 2019-07-25 |
| JP7354327B2 (ja) | 2023-10-02 |
| AU2017263886B2 (en) | 2023-11-09 |
| EP3455355B1 (en) | 2022-04-13 |
| WO2017197399A1 (en) | 2017-11-16 |
| CN109642229A (zh) | 2019-04-16 |
| JP7037504B2 (ja) | 2022-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7354327B2 (ja) | 生体液からの細胞外小胞の単離及びセルフリーｄｎａの同時単離のための自動及び手動方法 | |
| AU2019250221B2 (en) | Methods for isolating microvesicles and extracting nucleic acids from biological samples | |
| JP6449781B2 (ja) | 微細小胞の単離方法 | |
| US11268085B2 (en) | Methods for isolating microvesicles and extracting nucleic acids from biological samples | |
| HK40009837A (en) | Methods for isolating microvesicles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220511 |
|
| EEER | Examination request |
Effective date: 20220511 |
|
| EEER | Examination request |
Effective date: 20220511 |
|
| EEER | Examination request |
Effective date: 20220511 |
|
| EEER | Examination request |
Effective date: 20220511 |